Earnings results for Marinus Pharmaceuticals (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. is expected* to report earnings on 03/09/2021 before market open. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.52. The reported EPS for the same quarter last year was $-1.04.
Analyst Opinion on Marinus Pharmaceuticals (NASDAQ:MRNS)
10 Wall Street analysts have issued ratings and price targets for Marinus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $27.22, predicting that the stock has a possible upside of 62.81%. The high price target for MRNS is $35.00 and the low price target for MRNS is $18.00. There are currently 10 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Marinus Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $27.22, Marinus Pharmaceuticals has a forecasted upside of 62.8% from its current price of $16.72. Marinus Pharmaceuticals has received no research coverage in the past 90 days.
Dividend Strength: Marinus Pharmaceuticals (NASDAQ:MRNS)
Marinus Pharmaceuticals does not currently pay a dividend. Marinus Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Marinus Pharmaceuticals (NASDAQ:MRNS)
In the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock. Only 2.80% of the stock of Marinus Pharmaceuticals is held by insiders. 79.32% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Marinus Pharmaceuticals (NASDAQ:MRNS
Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($2.76) to ($2.00) per share. The P/E ratio of Marinus Pharmaceuticals is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Marinus Pharmaceuticals is -4.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Marinus Pharmaceuticals has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here